---
title: "U.S. FDA: Multiple pharmaceutical companies recall over 580,000 bottles of blood pressure medication contaminated with carcinogens"
description: "The U.S. FDA announced that several pharmaceutical companies are recalling over 580,000 bottles of the antihypertensive drug Prazosin Hydrochloride contaminated with carcinogens. This recall was volun"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/263774335.md"
published_at: "2025-10-31T14:43:41.000Z"
---

# U.S. FDA: Multiple pharmaceutical companies recall over 580,000 bottles of blood pressure medication contaminated with carcinogens

> The U.S. FDA announced that several pharmaceutical companies are recalling over 580,000 bottles of the antihypertensive drug Prazosin Hydrochloride contaminated with carcinogens. This recall was voluntarily initiated by Teva Pharmaceutical Industries in New Jersey and Mylan Health Services, as some medications may contain nitrosamine impurities, which are potential carcinogens. The FDA has classified this incident as a "Class II recall."

On October 31 local time, the U.S. Food and Drug Administration (FDA) announced that several pharmaceutical companies are recalling over 580,000 bottles of the antihypertensive drug Prazosin hydrochloride contaminated with carcinogens. The FDA stated that Teva Pharmaceutical Industries USA and Mylan Pharmaceuticals initiated a voluntary nationwide recall earlier this month. This medication is used to dilate blood vessels and lower blood pressure, and it is also commonly used to treat nightmares and sleep issues related to post-traumatic stress disorder. The FDA noted in its announcement that some batches of the drug may contain nitrosamine impurities, which are potential carcinogenic compounds formed during the production or storage of medications. The regulatory agency has classified this recall as a "Class II recall."

### Related Stocks

- [TEVA.US - Teva Pharmaceutical Industries](https://longbridge.com/en/quote/TEVA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug | Teva Pharmaceutical Industries Ltd. has entered a funding agreement with Royalty Pharma worth up to $500 million to adva | [Link](https://longbridge.com/en/news/272304721.md) |
| Judge Denies Teva Bid To Pause Paragard Copper Contraceptive Device Lawsuit Trial | A federal judge has denied Teva Pharmaceutical Industries' request to delay the first trial related to its Paragard IUD, | [Link](https://longbridge.com/en/news/272440521.md) |
| Options trades to play for a short squeeze in Hims & Hers as the pain piles up | Hims & Hers has faced significant challenges, including a lawsuit from Novo Nordisk and a 48% drop in stock value over t | [Link](https://longbridge.com/en/news/275789087.md) |
| Teva Canada Signs Agreement with Novartis to Commercialize Mayzent for MS Patients | Teva Canada Limited has signed a commercialization and supply agreement with Novartis Pharmaceuticals Canada Inc. for Ma | [Link](https://longbridge.com/en/news/274518158.md) |
| Teva posts FY non-GAAP net income of USD 3.41 billion, up 19% | Teva Pharmaceutical Industries Ltd. reported a FY non-GAAP net income of USD 3.41 billion, a 19% increase, with a non-GA | [Link](https://longbridge.com/en/news/274668783.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.